We are 2-Pipecoline CAS:109-05-7 manufacturer and supplier in China, Pls send inquiry of to email@example.com of visit www.nbinno.com our official website should you have any interests
Chemical Name: 2-Pipecoline
2-METHYLPIPERIDINE FOR SYNTHESIS
Molecular Weight: 99.17410
Physical and Chemical Properties:
Density: 0.844 g / mL at 25 ° C (lit.)
Boiling point: 118-119 ° C753 mm Hg (lit.)
Melting point: -4–5 ° C
Flash point: 47 ° F
Refractive index: n20 / D 1.446 (lit.)
Appearance: Clear yellow liquid
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Keep away from heat, sparks, and flame. Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances. Corrosives area.
Application: Applicationd as an organic synthesis reagent.
Related News: In terms of business, the industrial business increased by 7.97% year-on-year, while the revenue from the trading business shrank to a certain extent. The growth rate of industrial business was significantly slower than 24% in the first half of the year, showing that the growth rate of industrial business was lower in the third quarter, which was also the main reason for the decline in the company’s operating income in the third quarter. The company’s industrial business is mainly pesticide intermediates, accounting for about 85%. The scale of the pesticide intermediate business is large and the base is high, which is putting pressure on growth.Octadecyl acrylate Catalent’s clinical supply network includes nine cGMP-certified clinical packaging facilities across North America, Europe and Asia, and more than 50 strategically-located depots around the world, providing local and regional options for clinical storage, distribution, expiry update and relabeling services, and clinical returns management.1-difenilfosforiloxi-2,3,4,5,6-pentafluorobenceno CAS:138687-69-1 A Phase 1/2 trial of the combination therapy has been fully enrolled, and the preliminary efficacy and safety data was presented at The American Society of Hematology (ASH) Annual Meeting in December 2018.2620-76-0 A Phase 1/2 trial of the combination therapy has been fully enrolled, and the preliminary efficacy and safety data was presented at The American Society of Hematology (ASH) Annual Meeting in December 2018.Here’s what Apple told CNN Business in a statement: